Is Roivant Sciences Ltd. (ROIV) a Buy, Sell, or Hold?
NASDAQ : ROIV
Roivant Sciences Ltd. — Institutional Ownership
$34.6 USD
$0.01 (0.03%)
- Volume
- 5.81M
- Average Volume
- 5.82M
- Market Capitalization
- $25B
- P/E Ratio
- -76.89
- Dividend Yield
- 0.00%
- Price Target
- $38.00
- Year High
- $37.00
- Year Low
- $10.90
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.37
Institutional Ownership Summary
Institutional Ownership %
4.41%
Investors Holding
174
change: -287.0 | last: 461
Increased Positions
109
change: -153.0 | last: 262
Reduced Positions
36
change: -91.0 | last: 127
New Positions
47
change: -43.0 | last: 90
Sold Positions
318
change: 267.0 | last: 51
Total Calls
27400
Total Puts
27000
Put-Call Ratio
0.99
change: 23.0051 | last: 0.7554
Total Invested
1.08B
Beneficial Ownership Filings
| Filing Date | Reporting Person | Amount Beneficially Owned | % of Class |
|---|---|---|---|
| 2026-05-12 | Morgan Stanley | 49.47M | 6.90% |
| 2026-05-06 | Ramaswamy Vivek | 25.53M | 3.60% |
| 2026-03-27 | The Vanguard Group | - | 0.00% |
| 2026-03-06 | FMR LLC | 73.64M | 10.30% |
| 2026-02-17 | SB Investment Advisers (UK) Limited | 16.41M | 2.30% |
| 2026-02-13 | Ramaswamy Vivek | 48.43M | 6.80% |
| 2026-02-11 | Morgan Stanley | 55.49M | 8.00% |
| 2026-02-05 | FMR LLC | 65.78M | 9.50% |
| 2025-12-12 | Roivant Sciences Ltd. | 113.33M | 55.90% |
| 2025-11-14 | VIKING GLOBAL INVESTORS LP | 23.59M | 3.40% |
| 2025-11-14 | SB Investment Advisers (UK) Limited | 40.32M | 5.80% |
| 2025-08-14 | VIKING GLOBAL INVESTORS LP | 34.24M | 5.02% |
| 2025-08-14 | QVT Financial LP | 29.38M | 4.30% |
| 2025-08-07 | Morgan Stanley | 37.65M | 5.50% |
| 2025-08-06 | FMR LLC | 55.51M | 8.20% |
| 2025-05-15 | Ramaswamy Vivek | 82.96M | 11.63% |
| 2025-05-15 | VIKING GLOBAL INVESTORS LP | 46.01M | 6.40% |
| 2025-05-15 | Ramaswamy Vivek | 82.96M | 11.20% |
| 2025-04-21 | Roivant Sciences Ltd. | 96.66M | 56.90% |
| 2025-02-25 | Roivant Sciences Ltd. | 38.85M | 20.50% |
| 2025-02-18 | Roivant Sciences Ltd. | 38.85M | 20.50% |
| 2025-02-14 | SB Investment Advisers (UK) Limited | 62.06M | 8.50% |
| 2025-02-14 | QVT Financial LP | 65.79M | 9.22% |
| 2025-01-15 | Roivant Sciences Ltd. | 96.66M | 56.90% |
| 2024-11-12 | Abigail P. Johnson | 49.15M | 6.65% |
| 2024-11-12 | FMR LLC | 49.15M | 6.65% |
| 2024-11-08 | BlackRock, Inc. | 41.96M | 5.70% |
| 2023-10-04 | Roivant Sciences Ltd. | 79.82M | 55.30% |
| 2022-02-14 | Viking Global Opportunities Portfolio GP LLC | 35.54M | 5.10% |
| 2022-02-14 | Viking Global Equities II LP | 751.77K | 0.10% |
| 2022-02-14 | Viking Long Fund Master Ltd. | 15.11M | 2.20% |
| 2022-02-14 | O. Andreas Halvorsen | 88.24M | 12.80% |
| 2022-02-14 | QVT Financial LP | 129.39M | 18.70% |
| 2022-02-14 | QVT Financial GP LLC | 129.39M | 18.70% |
| 2022-02-14 | QVT Financial Investment Cayman Ltd. | 39.78M | 5.75% |
| 2022-02-14 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 35.54M | 5.10% |
| 2022-02-14 | SB Investment Advisers (UK) Limited | 99.38M | 14.40% |
| 2022-02-14 | SVF GP (Jersey) Limited | 99.38M | 14.40% |
| 2022-02-14 | SoftBank Vision Fund LP | 99.38M | 14.40% |
| 2022-02-14 | SVF Holdings (UK) LLP | 99.38M | 14.40% |
| 2022-02-14 | SVF Investments (UK) Limited | 99.38M | 14.40% |
| 2022-02-14 | Vivek Ramaswamy | 74.4M | 10.50% |
| 2022-02-14 | Viking Global Investors LP | - | 12.80% |
| 2022-02-14 | QVT Roiv Hldgs Offshore Ltd. | 39.66M | 5.73% |
| 2022-02-14 | Viking Global Performance LLC | 37.59M | 5.40% |
| 2022-02-14 | Viking Global Equities Master Ltd. | 36.84M | 5.30% |
| 2022-02-14 | Viking Long Fund GP LLC | 15.11M | 2.20% |
| 2022-02-14 | Viking Global Opportunities Parent GP LLC | 35.54M | 5.10% |
| 2022-02-14 | Viking Global Opportunities GP LLC | 35.54M | 5.10% |
| 2022-02-14 | David C. Ott | 88.24M | 12.80% |
| 2022-02-14 | Rose S. Shabet | 88.24M | 12.80% |
| 2022-02-10 | Dexcel Pharma Technologies Ltd. | 643.84K | 0.09% |
| 2022-02-10 | Dexxon Holdings Ltd. | 98.17M | 14.19% |
| 2022-02-10 | Dan Oren | 98.81M | 14.28% |
| 2022-02-01 | Sumitomo Chemical Co., Ltd. | 86.37M | 12.48% |
| 2022-02-01 | Sumitomo Dainippon Pharma Co., Ltd. | 86.37M | 12.48% |
| 2020-02-28 | Roivant Sciences Ltd. | 18.58M | 47.10% |
| 2017-02-10 | Roivant Sciences Ltd. | 37.23M | 61.80% |
| 2016-02-16 | Roivant Sciences Ltd. | 75M | 75.60% |
| 2015-08-26 | Roivant Sciences Ltd. | 16.01M | 29.50% |
| 2015-08-26 | Vivek Ramaswamy | 16.08M | 29.60% |
| 2015-03-16 | Vivek Ramaswamy | 16.07M | 34.50% |
| 2015-03-16 | Roivant Sciences Ltd. | 16.01M | 34.40% |
ROIV Enterprise Value History
Annual
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $27.70 | 693.86M | $19.22B | $1.42B | $107.44M | $17.9B |
| 2025-03-31 | $10.09 | 725.4M | $7.32B | $2.72B | $100.17M | $4.7B |
| 2024-03-31 | $10.43 | 783.25M | $8.17B | $6.54B | $499.75M | $2.13B |
| 2023-03-31 | $7.38 | 712.79M | $5.26B | $1.68B | $481.4M | $4.06B |
| 2022-03-31 | $4.94 | 669.75M | $3.31B | $2.06B | $283.89M | $1.53B |
| 2021-03-31 | $9.78 | 684.79M | $6.7B | $2.13B | $244.98M | $4.81B |
| 2020-03-31 | $10.40 | 684.79M | $7.12B | $2.19B | $180.88M | $5.12B |
Quarterly
| Date | Stock Price | Shares Outstanding | Market Cap | Cash & Equivalents | Total Debt | Enterprise Value |
|---|---|---|---|---|---|---|
| 2026-03-31 | $27.70 | 702.13M | $19.45B | $1.42B | $107.44M | $18.13B |
| 2025-12-31 | $21.70 | 696.86M | $15.12B | $1.48B | $207.44M | $13.85B |
| 2025-09-30 | $15.13 | 680.95M | $10.3B | $1.24B | $98.85M | $9.16B |
| 2025-06-30 | $11.27 | 680.29M | $7.67B | $1.24B | $99.69M | $6.53B |
| 2025-03-31 | $10.09 | 707.3M | $7.14B | $2.72B | $100.17M | $4.52B |
| 2024-12-31 | $11.83 | 722.72M | $8.55B | $1.99B | $100.31M | $6.66B |
| 2024-09-17 | $12.05 | 735.47M | $8.86B | $1.96B | $52.71M | $6.96B |
| 2024-06-30 | $10.83 | 735.82M | $7.97B | $5.68B | $379.06M | $2.66B |
| 2024-03-31 | $10.43 | 802.86M | $8.37B | $6.54B | $499.75M | $2.34B |
| 2023-12-31 | $11.23 | 800.59M | $8.99B | $6.67B | $506.58M | $2.83B |
| 2023-09-30 | $11.68 | 770.23M | $9B | $1.41B | $497.98M | $8.08B |
| 2023-06-30 | $10.08 | 759.27M | $7.65B | $1.44B | $492.64M | $6.71B |